Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression

Anna Billeschou Bomholt, Christian Dall Johansen, Jens Bager Christensen, Sasha Alexandra Sampson Kjeldsen, Katrine Douglas Galsgaard, Marie Winther-Sørensen, Reza Serizawa, Mads Hornum, Esteban Porrini, Jens Pedersen, Cathrine Ørskov, Lise Lotte Gluud, Charlotte Mehlin Sørensen, Jens Juul Holst, Reidar Albrechtsen, Nicolai Jacob Wewer Albrechtsen


Glucagon is a major regulator of metabolism and drugs targeting the glucagon receptor (GCGR) are being developed. Insight into tissue and cell-specific expression of the GCGR is important to understand the biology of glucagon and to differentiate between direct and indirect actions of glucagon. However, it has been challenging to localize the GCGR in tissue due to low expression levels and lack of specific methods. Immunohistochemistry has frequently been used for GCGR localization, but antibodies targeting G-protein-coupled-receptors may be inaccurate. We evaluated all currently commercially available GCGR antibodies. The antibody, ab75240 (Antibody no. 11) was found to perform best among the twelve antibodies tested and using this antibody we found expression of the GCGR in the kidney, liver, preadipocytes, pancreas, and heart. Three antibody-independent approaches all confirmed the presence of the GCGR within the pancreas, liver and the kidneys. GCGR expression should be evaluated by both antibody and antibody-independent approaches.

Original languageEnglish
Article number1278
JournalCommunications biology
Issue number1
Pages (from-to)1278
Publication statusPublished - 22 Nov 2022


Dive into the research topics of 'Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression'. Together they form a unique fingerprint.

Cite this